Daniel C Cho
Overview
Explore the profile of Daniel C Cho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1454
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sanborn R, Hamid O, de Vries E, Ott P, Garcia-Corbacho J, Boni V, et al.
J Immunother Cancer
. 2021 Jul;
9(7).
PMID: 34301808
Background: Probody® therapeutics are antibody prodrugs designed to be activated by tumor-associated proteases. This conditional activation restricts antibody binding to the tumor microenvironment, thereby minimizing 'off-tumor' toxicity. Here, we report...
12.
Diab A, Tykodi S, Daniels G, Maio M, Curti B, Lewis K, et al.
J Clin Oncol
. 2021 Jul;
39(26):2914-2925.
PMID: 34255535
Purpose: Therapies that produce deep and durable responses in patients with metastatic melanoma are needed. This phase II cohort from the international, single-arm PIVOT-02 study evaluated the CD122-preferential interleukin-2 pathway...
13.
Mcdermott D, Lee J, Bjarnason G, Larkin J, Gafanov R, Kochenderfer M, et al.
J Clin Oncol
. 2021 Feb;
39(9):1020-1028.
PMID: 33529051
Purpose: Pembrolizumab, a programmed death 1 inhibitor, demonstrated promising single-agent activity in untreated patients with various cancer types. The phase II KEYNOTE-427 study evaluated efficacy and safety of single-agent pembrolizumab...
14.
Atkins M, Plimack E, Puzanov I, Fishman M, Mcdermott D, Cho D, et al.
Eur J Cancer
. 2021 Jan;
145:1-10.
PMID: 33412465
Background: Axitinib plus pembrolizumab showed superior overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) versus sunitinib in a randomised phase III trial in patients with advanced renal-cell...
15.
Toth A, Cho D
J Kidney Cancer VHL
. 2020 Dec;
7(4):17-26.
PMID: 33364146
Multiple combinational regimens have recently been approved and are now considered the standard of care for patients with advanced clear cell renal cell carcinoma (RCC). Several additional combinational regimens are...
16.
Moiseyenko A, Muggia F, Condamine T, Pulini J, Janik J, Cho D
Gynecol Oncol Rep
. 2020 Oct;
34:100655.
PMID: 33083509
Agonists of the co-stimulatory molecule OX40 (CD134) are in clinical assessment alone and in combination with other immunotherapies. Recent pre-clinical studies have suggested that concurrent administration of OX40 agonists with...
17.
Martini J, Plimack E, Choueiri T, Mcdermott D, Puzanov I, Fishman M, et al.
Clin Cancer Res
. 2020 Aug;
26(21):5598-5608.
PMID: 32816890
Purpose: Combined axitinib/pembrolizumab is approved for advanced renal cell carcinoma (aRCC). This exploratory analysis examined associations between angiogenic and immune-related biomarkers and outcomes following axitinib/pembrolizumab treatment. Patients And Methods: Prospectively...
18.
Shapiro G, LoRusso P, Cho D, Musib L, Yan Y, Wongchenko M, et al.
Invest New Drugs
. 2020 Aug;
39(1):163-174.
PMID: 32737717
Background: This Phase Ib study explored combination dosing of the allosteric MEK1/2 inhibitor cobimetinib and the ATP-competitive pan-AKT inhibitor ipatasertib. Methods: Patients with advanced solid tumors were enrolled to two...
19.
Diab A, Tannir N, Bentebibel S, Hwu P, Papadimitrakopoulou V, Haymaker C, et al.
Cancer Discov
. 2020 May;
10(8):1158-1173.
PMID: 32439653
This single-arm, phase I dose-escalation trial (NCT02983045) evaluated bempegaldesleukin (NKTR-214/BEMPEG), a CD122-preferential IL2 pathway agonist, plus nivolumab in 38 patients with selected immunotherapy-naïve advanced solid tumors (melanoma, renal cell carcinoma,...
20.
Cho D, Cohen M, Panka D, Collins M, Ghebremichael M, Atkins M, et al.
Clin Cancer Res
. 2019 Jul;
25(13):4194.
PMID: 31263033
No abstract available.